ES2113927T3 - Compuestos utiles como antagonistas de leucotrienos. - Google Patents

Compuestos utiles como antagonistas de leucotrienos.

Info

Publication number
ES2113927T3
ES2113927T3 ES92309461T ES92309461T ES2113927T3 ES 2113927 T3 ES2113927 T3 ES 2113927T3 ES 92309461 T ES92309461 T ES 92309461T ES 92309461 T ES92309461 T ES 92309461T ES 2113927 T3 ES2113927 T3 ES 2113927T3
Authority
ES
Spain
Prior art keywords
cr1r2
hydrogen
useful compounds
leucotrene
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309461T
Other languages
English (en)
Inventor
Jeremy Gilmore
John Richard Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of ES2113927T3 publication Critical patent/ES2113927T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

UN COMPUESTO QUE TIENE UNA ACTIVIDAD FAMACEUTICA DE LA FORMULA EN QUE A ES HIDROGENO O -(CR1R2)R3 DONDE X ES DE 1 A 4, R1 Y R2 SON CADA UNO HIDROGENO O ALQUILO C1-4 Y R3 ES -CN, -COOH, TETRAZOLILO O CONHSO2R4 DONDE R4 ES FENILO OPCIONALMENTE SUSTITUIDO Y SE SELECCIONA DEL DONDE R5 Y R6 SON CADA UNO HIDROGENO, ALQUILO C1-4 O -(CR1R2)XR3 DONDE X ES DE 1 A 4 Y R1, R2 Y R3 SON COMO SE HA DEFINIDO ARRIBA; SIEMPRE Y CUANDO SI A ES HIDROGENO AL MENOS UNO DE R5, R6 Y R7 SEA -(CR1R2)XR3 Y SIEMPRE Y CUANDO SI ES A SEA -(CR1R2)XR3 Y SI X ES DE 1 A 4 ENTONCES R3 SEA -CONHSO2R4; Y LAS SALES Y ESTERES DEL MISMO.
ES92309461T 1991-10-24 1992-10-16 Compuestos utiles como antagonistas de leucotrienos. Expired - Lifetime ES2113927T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919122590A GB9122590D0 (en) 1991-10-24 1991-10-24 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2113927T3 true ES2113927T3 (es) 1998-05-16

Family

ID=10703466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309461T Expired - Lifetime ES2113927T3 (es) 1991-10-24 1992-10-16 Compuestos utiles como antagonistas de leucotrienos.

Country Status (9)

Country Link
US (1) US5410061A (es)
EP (1) EP0539117B1 (es)
JP (1) JPH05345778A (es)
AT (1) ATE163933T1 (es)
CA (1) CA2081133A1 (es)
DE (1) DE69224697T2 (es)
DK (1) DK0539117T3 (es)
ES (1) ES2113927T3 (es)
GB (1) GB9122590D0 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3578495A (en) * 1994-09-30 1996-04-26 Nippon Chemiphar Co. Ltd. Quinoline derivative
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
WO1998015530A1 (fr) * 1996-10-08 1998-04-16 Fujisawa Pharmaceutical Co., Ltd. Derives d'indol
MXPA02003122A (es) 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
EP1070705A4 (en) * 1998-04-06 2002-04-17 Fujisawa Pharmaceutical Co INDOLE DERIVATIVES
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
KR20070091607A (ko) * 2004-10-12 2007-09-11 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 설폰아미드 주변 치환된바이사이클릭 화합물
US8076365B2 (en) * 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007137042A2 (en) 2006-05-16 2007-11-29 Decode Genetics, Ehf. Process for preparing 7- (acryl0yl) -ind0les
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
ES2442717T3 (es) 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2020206036A1 (en) * 2019-01-11 2021-08-05 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
DE69009887T2 (de) * 1989-07-26 1994-09-22 Ici Pharma Bizyklische Derivate.
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
AU654140B2 (en) * 1990-07-31 1994-10-27 Lilly Industries Limited N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them
EP0505122A1 (en) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, alpha-dialkylbenzyl derivatives

Also Published As

Publication number Publication date
EP0539117B1 (en) 1998-03-11
DK0539117T3 (da) 1998-09-28
DE69224697T2 (de) 1998-07-16
ATE163933T1 (de) 1998-03-15
EP0539117A1 (en) 1993-04-28
US5410061A (en) 1995-04-25
GB9122590D0 (en) 1991-12-04
DE69224697D1 (de) 1998-04-16
JPH05345778A (ja) 1993-12-27
CA2081133A1 (en) 1993-04-25

Similar Documents

Publication Publication Date Title
ES2113927T3 (es) Compuestos utiles como antagonistas de leucotrienos.
DE69619711D1 (de) Retinoid-potenzierende verbindungen
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
RS93504A (en) Pyridine compounds or salts thereof and herbicides containing the same
CR6805A (es) Derivados novedosos de eter de propargil-fenil
ECSP034564A (es) Composicion pesticida
ATE188472T1 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
ATE96273T1 (de) Pflanzenschuetzende mittel auf basis von pyrazolcarbonsaeurederivaten.
ATE124037T1 (de) Pleuromutiline.
TR200400376T4 (tr) Yeni, ilaç olarak kullanılabilen antikolinerjikler ve bunların imalatı için yöntem
PA8467101A1 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
DE3774591D1 (de) Heterocyclische verbindungen.
ES2141262T3 (es) Amidas ciclicas fungicidas.
PT1140916E (pt) Acetais heteroarilo ciclicos
ATE207906T1 (de) Phenylimidazolidine und deren verwendung als anti-androgene mittel
ATE383861T1 (de) Vasopressin antagonist und oxytocin antagonist
MX9305091A (es) Compuestos benzoheterociclicos.
DE69131475D1 (de) Plättchenaggregationshemmstoffe
DE69326650D1 (de) Piperidinderivate von Benzimidazole als antihistaminische und antiallergische Mittel
ES2194486T3 (es) Derivados de diacilhidrazina como inhibidores de integrina.
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
IT1224416B (it) Chelanti macrociclici e loro chelati
BG99863A (en) Antagonists of fibrogenous receptor
AR246289A1 (es) Composicion inhibidora de polimerizacion.
HUP0101132A2 (hu) Amidvegyületet tartalmazó, szinergetikus hatású fungicid hatóanyag keverék és alkalmazása

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539117

Country of ref document: ES